Final overall survival analysis for the phase II RECORD-3 Study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.
Fiche publication
Date publication
février 2017
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GEOFFROIS Lionnel
Tous les auteurs :
Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ
Lien Pubmed
Résumé
RECORD-3 compared everolimus and sunitinib as first-line therapy, and the sequence of everolimus followed by sunitinib at progression compared with the opposite (standard) sequence in patients with metastatic renal cell carcinoma (mRCC). This final overall survival (OS) analysis evaluated mature data for secondary end points.
Mots clés
everolimus, renal cell carcinoma, sequential targeted therapy, sunitinib
Référence
Ann. Oncol.. 2017 Feb;: